<DOC>
	<DOC>NCT01703845</DOC>
	<brief_summary>The primary objective of this study is to assess pharmacokinetics of tiotropium + olodaterol fixed-dose combination (2.5 µg/ 5 µg, 5 µg/ 5 µg) delivered by the RESPIMAT inhaler after 3 weeks once daily treatment in Japanese patients with COPD.</brief_summary>
	<brief_title>A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criteria: 1. Diagnosis of chronic obstructive pulmonary disease 2. Relatively stable airway obstruction with post FEV1=&lt;30% of predicted normal and&lt; 80% predicted normal and post FEV1/FVC &lt;70% 3. Male or female Japanese patients, 40 years of age or older 4. Smoking history of more than 10 pack years Exclusion criteria: 1. Significant disease other than COPD 2. Clinically relevant abnormal lab values 3. History of asthma 4. Diagnosis of thyrotoxicosis 5. Diagnosis of paroxysmal tachycardia 6. A marked baseline prolongation of QT/QTc interval 7. A history of additional risk factors for Torsade de Pointes (TdP) 8. History of myocardial infarction within 1 year of screening visit 9. Unstable or lifethreatening cardiac arrhythmia 10. Hospitalization for heart failure within the past year 11. Known active tuberculosis 12. Malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years 13. History of lifethreatening pulmonary obstruction 14. History of cystic fibrosis 15. Clinically evident bronchiectasis 16. History of significant alcohol or drug abuse 17. Thoracotomy with pulmonary resection 18. Oral ßadrenergics 19. Oral corticosteroid medication at unstable doses 20. Regular use of daytime oxygen therapy for more than one hour per day 21. Pulmonary rehabilitation program in the six weeks prior to the screening visit 22. Investigational drug within one month or six half lives (whichever is greater) prior to screening visit 23. Known hypersensitivity to ßadrenergic drugs, anticholinergics, BAC, EDTA 24. Pregnant or nursing women 25. Women of childbearing potential not using a highly effective method of birth control 26. Patients who have previously been randomized in this study or are currently participating in another study 27. Patients who are unable to comply with pulmonary medication restrictions 28. Patients with narrowangle glaucoma or micturition disorder due to prostatic hyperplasia etc 29. Patients being treated with medications that prolong the QT/QTc interval</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>